Results from the BouNDless trial demonstrated that ND0612 met its primary endpoint and the first four secondary endpoints, which showed that it was superior to oral immediate-release LD/CD at increasing ‘on’ time in patients without causing dyskinesia and reducing ‘off’ time, after 12 weeks.
NeuroDerm shares positive phase 3 results... - Cure Parkinson's
NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
Hopefully it will be approved soon along with the Abbvie pump and the competition make them more affordable.
Not what you're looking for?
You may also like...
Phase 3 Positive Topline Results for Tavapadon
unces-positive-topline-results-0
Tavapadon met the primary endpoint in the pivotal Phase 3...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
there is a tendency for only data with positive results to be published.7 There has only been one...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
with #Parkinsons to proceed; 6 months; double-blind, placebo-controlled; 2 doses; N=450; 1#...
Related Posts
- Parkinson’s disease stem cell therapy research update
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
Potential disease-modifying therapy enters Phase 2- A potential case of remission of Parkinson’s disease
- Cuban drug for Parkinson’s and Alzheimer’s diseases moves to phase III
